Shanghai Henlius Biotech Inc. (HKG: 2696) has entered into a partnership and licensing agreement with U.S.-based Sermonix Pharmaceuticals Inc. for exclusive development, manufacturing, and commercialization rights in China for the investigational drug lasofoxifene. This ESR1 antagonist is being developed as a treatment for breast cancer.
Under the terms of the agreement, Henlius will gain exclusive rights, including sub-licensing rights, for lasofoxifene in at least two indications of ER+/HER2- breast cancer within China. Sermonix will retain rights to the drug outside of the Chinese market. The agreement includes potential milestone payments of up to $58 million for Sermonix, in addition to royalties on future sales.- Flcube.com
